|
|
Volumn 15, Issue 5, 2016, Pages 295-297
|
|
Drug developers delve into the cell's trash-disposal machinery
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BCR ABL PROTEIN;
BORTEZOMIB;
CARFILZOMIB;
CYSTEINE PROTEINASE;
DEUBIQUITINASE;
PROTEASOME;
PROTEASOME INHIBITOR;
PROTEIN TYROSINE KINASE INHIBITOR;
THALIDOMIDE;
UBIQUITIN;
UBIQUITIN PROTEIN LIGASE E3;
VON HIPPEL LINDAU PROTEIN;
ARTICLE;
CANCER RESISTANCE;
CHRONIC MYELOID LEUKEMIA;
DRUG TARGETING;
HUMAN;
MULTIPLE MYELOMA;
NONHUMAN;
PRIORITY JOURNAL;
PROTEIN DEGRADATION;
UBIQUITINATION;
ANIMAL;
CHEMISTRY;
DRUG DEVELOPMENT;
DRUG EFFECTS;
METABOLISM;
NEOPLASMS;
ANIMALS;
DEUBIQUITINATING ENZYMES;
DRUG DISCOVERY;
HUMANS;
NEOPLASMS;
PROTEASOME ENDOPEPTIDASE COMPLEX;
PROTEASOME INHIBITORS;
PROTEOLYSIS;
UBIQUITIN;
|
|
EID: 84965170715
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd.2016.86 Document Type: Article |
|
Times cited : (13)
|
|
References (0)
|
